Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immunovant (IMVT)
NASDAQ:IMVT
Holding IMVT?
Track your performance easily
IMVT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$24.61 - $45.58
Previous Close$25.86
Volume3.24M
Average Volume (3M)849.70K
Market Cap
$3.77B
Enterprise Value$3.29B
Total Cash (Recent Filing)$472.94M
Total Debt (Recent Filing)$47.00K
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Feb 12, 2025EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding146,784,639
10 Day Avg. Volume859,727
30 Day Avg. Volume849,703
Standard Deviation0.24
R-Squared0.02
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)8.45
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.67
Forecast
1Y Price Target
$49.13Price Target Upside89.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Immunovant News
PremiumCompany Announcements
Immunovant’s Strategic Advances in Autoimmune Therapies
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignThe Phase 3 trial design for IMVT-1402 is viewed positively, with expectations that it will differentiate itself from existing treatments and support enrollment.
Market OpportunityGraves' disease is likely a big commercial opportunity for IMVT-1402, with potential to address a significant number of patients struggling with current treatments.
Treatment InnovationIMVT-1402 has a high potential for success in treating Graves' disease, where a significant percentage of patients are inadequately treated.
Bears Say
Clinical TrialsThe TED launch is delayed to 2027 due to data push impacted by enrollment competition from other trials.
Market SentimentThe short interest for the company stands at 20.3% of the float.
Treatment RisksRadioactive iodine for GD is not used often outside of the US since it has severe side effects that are undesirable, such as secondary carcinoma, exacerbation of eye disease (i.e. TED), issues with pregnancies.
---
Ownership Overview
2.73% Insiders
16.21% Mutual Funds
24.73% Other Institutional Investors
48.08% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IMVT FAQ
What was Immunovant’s price range in the past 12 months?
Immunovant lowest stock price was $24.61 and its highest was $45.58 in the past 12 months.
What is Immunovant’s market cap?
Currently, no data Available
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Feb 12, 2025 which is in 52 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Nov 07, 2024. The company reported -$0.74 earnings per share for the quarter, missing the consensus estimate of -$0.589 by -$0.151.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -$0.75.
How many shares outstanding does Immunovant have?
Immunovant has 146,784,640 shares outstanding.
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -$0.74 in its last earnings report, missing expectations of -$0.589. Following the earnings report the stock price went down -4.742%.
Which hedge fund is a major shareholder of Immunovant?
Among the largest hedge funds holding Immunovant’s share is Perceptive Advisors LLC. It holds Immunovant’s shares valued at 68M.
---
Immunovant Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.13 (89.98% Upside)
$49.13 (89.98% Upside)
Blogger Sentiment
Bullish
IMVT Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 815.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.52%
12-Months-Change
Fundamentals
Return on Equity
-92.17%
Trailing 12-Months
Asset Growth
76.57%
Trailing 12-Months
Company Description
Immunovant
Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.
---
IMVT Stock 12 Month Forecast
Average Price Target
$49.13
▲(89.98% Upside)
Technical Analysis
Best Analysts Covering IMVT
1 Year
1 Year Success Rate
10/18 ratings generated profit
1 Year Average Return
+77.66%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +77.66% per trade.
---